Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity ATLANTA, GA - June 8, 2026 ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has ...
Immune checkpoint inhibitors have transformed the management of advanced malignancies by releasing the brakes on antitumour T-cell responses. Agents targeting programmed cell death protein 1 (PD-1), ...
Immune checkpoint inhibitors (ICIs) have redefined the therapeutic landscape of oncology, producing durable responses across multiple tumor types and treatment settings. However, widespread adoption ...
Trials such as NICHE-2, 4 NICHE-3, 15 RESET-C, 16 NEOPRISM-CRC, 13 and NEOSHOT 3 (ClinicalTrials.gov identifier: NCT05890742) evaluate short-course neoadjuvant immune checkpoint blockade followed by ...
T cells lie at the heart of adaptive immunity, recognising peptide antigens via the T cell receptor (TCR) and undergoing activation only when signals from co-stimulatory receptors complement antigen ...
Despite remarkable advances in immunotherapy and targeted agents, therapeutic resistance remains the central obstacle in managing metastatic skin cancer. In ...
Please provide your email address to receive an email when new articles are posted on . IBC-Ab002 treatment doses ranged from 1 mg/kg to 30 mg/kg and were given four times. No safety concerns arose in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results